
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Somatoform Disorder
FamilyDoctor.org
Somatoform Disorders Overview
eMedicine from WebMD
Information: Somatoform Disorders
Merck




